Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACsBRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. NASDAQ:NRIX, a clinical-stage biopharmaceutical company focused on the discovery, development and com…